Research Topics
Genomes and GenesSpecies | Donald F BrophySummaryAffiliation: Virginia Commonwealth University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Overcoming delayed in-vitro response to rFVIIa: effects of rFVIIa and rFVIIa analogue (vatreptacog alfa) concentration escalation in whole blood assaysDonald F Brophy
Coagulation Advancement Laboratory, Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond, VA, USA
Blood Coagul Fibrinolysis 22:541-6. 2011..28 μg/ml. Vatreptacog alfa produced more pronounced coagulation effects at lower concentrations than rFVIIa; and the 0.56 μg/ml concentration completely normalized responses in all patients...- Monitoring rFVIIa 90 μg kg⁻¹ dosing in haemophiliacs: comparing laboratory response using various whole blood assays over 6 hD F Brophy
Coagulation Advancement Laboratory, Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University VCU, Richmond, VA, USA
Haemophilia 17:e949-57. 2011..The PCF and CEM were correlated to FVII:C and characterized the dynamics of platelet function and clot strength over the rFVIIa dosing interval. The clinical significance of these findings needs additional study... - Factor VIIa analog has marked effects on platelet function and clot kinetics in blood from patients with hemophilia ADonald F Brophy
School of Pharmacy, Coagulation Advancement Laboratory, Virginia Commonwealth University, Richmond, VA, USA
Blood Coagul Fibrinolysis 21:539-46. 2010..HAS and TEG assays provided similar estimates of FOT and R, however CEM appeared to be more sensitive than MA to changes in clot firmness... - Characterizing hospitalizations of end-stage renal disease patients on dialysis and inpatient utilization of erythropoiesis-stimulating agent therapyDonald F Brophy
Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298, USA
Ann Pharmacother 44:43-9. 2010..Studies have found that hemoglobin concentrations are often low among dialysis patients after hospital discharge, yet little is known about inpatient anemia treatment... - A pilot study of genetic polymorphisms and hemodialysis vascular access thrombosisDonald F Brophy
Department of Pharmacy, Virginia Commonwealth University, Richmond, 23298 0533, USA
Hemodial Int 13:19-26. 2009..The NOS3 420 bp allele may have an association with thrombosis; however, further epidemiologic data evaluating large dialysis registries are needed to confirm our observation... 
Use of enoxaparin in patients with chronic kidney disease: safety considerationsDonald F Brophy
Department of Pharmacy, Virginia Commonwealth University/Medical College of Virginia Campus, Richmond, Virginia 23298-0533, USA
Drug Saf 30:991-4. 2007- Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patientsD F Brophy
Coagulation Special Studies Laboratory, Department of Pharmacy of Virginia Commonwealth University, Richmond, VA 23298, USA
Haemophilia 13:533-41. 2007..NN1731 may be a promising haemostatic agent for patients with bleeding disorders. These results should be confirmed in an in vivo study... - The effect of uremia on platelet contractile force, clot elastic modulus and bleeding time in hemodialysis patientsDonald F Brophy
Department of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298 0533, USA
Thromb Res 119:723-9. 2007.... - Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal diseaseD F Brophy
Department of Pharmacy Practice, Virginia Commonwealth University Medical College of Virginia, Richmond, VA 23298, USA
J Thromb Haemost 4:372-6. 2006..This phenomenon appears to occur despite judicious monitoring of antifactor Xa (aFXa) activity. Better monitoring parameters are needed to quantify the anticoagulant effects of enoxaparin in the ESRD population... - Darbepoetin alfa therapeutic interchange protocol for anemia in dialysisDonald F Brophy
School of Pharmacy, Virginia Commonwealth University Medical College of Virginia VCU MCV, Richmond, VA 23298 0533, USA
Ann Pharmacother 39:1808-11. 2005..These medications improve patient outcomes and quality of life. Their costs, however, remain a major barrier for health systems... - Pharmacoeconomic considerations in the health system management of anaemia in patients with chronic kidney disease and end stage renal diseaseDonald F Brophy
Department of Pharmacy, Virginia Commonwealth University Medical College of Virginia School of Pharmacy, Richmond, Virginia 23298 0533, USA
Expert Opin Pharmacother 4:1461-9. 2003..This review details these important pharmacoeconomic considerations... - Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation timeDonald F Brophy
Department of Pharmacy Practice, Virginia Commonwealth University Medical College of Virginia, Richmond, VA, USA
Am J Kidney Dis 44:270-7. 2004.... - Role of N-acetylcysteine in the prevention of radiocontrast-induced nephropathyDonald F Brophy
Department of Pharmacy, Virginia Commonwealth University Medical College of Virginia School of Pharmacy, PO Box 980533, Richmond, VA 23298 0533, USA
Ann Pharmacother 36:1466-70. 2002..To examine the role of N-acetylcysteine (NAC) in the prevention of radiocontrast-induced nephropathy (RIN)... - The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapiesDonald F Brophy
Department of Pharmacy, Coagulation Special Studies Laboratory, Virginia Commonwealth University/Medical College of Virginia (VCU/MCV, Richmond, Virginia, USA
J Clin Pharmacol 46:887-94. 2006..Therefore, these subjects exhibit greater thrombin generation time prolongation despite similar antifactor Xa exposure. Further large-scale studies are needed to corroborate the results of this exploratory pilot study... - Examining platelet-fibrin interactions during traumatic shock in a swine model using platelet contractile force and clot elastic modulusNathan J White
Reanimation Engineering Science Center, Department of Emergency Medicine, Virginia Commonwealth University, Richmond, Virginia, USA
Blood Coagul Fibrinolysis 22:379-87. 2011.... 
Systemic central venous oxygen saturation is associated with clot strength during traumatic hemorrhagic shock: A preclinical observational modelNathan J White
Reanimation Engineering Science Center, Virginia Commonwealth University, Richmond, 23298, USA
Scand J Trauma Resusc Emerg Med 18:64. 2010..We hypothesize that oxygen transport measurements will be associated with clot strength during traumatic shock, and test this hypothesis using a swine model of controlled traumatic shock...- Characterization of the plasma and blood anticoagulant potential of structurally and mechanistically novel oligomers of 4-hydroxycinnamic acidsBrian L Henry
Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, Virginia, USA
Blood Coagul Fibrinolysis 20:27-34. 2009..These results demonstrate that sulfated DHPs possess good in-vitro and ex-vivo activity, which will likely be improved through a rational design... - Prospective, randomized comparison of lansoprazole suspension, and intermittent intravenous famotidine on gastric pH and acid production in critically ill neurosurgical patientsGretchen M Brophy
Departments of Pharmacotherapy and Outcomes Sciences and Neurosurgery, Virginia Commonwealth University School of Pharmacy, P O Box 980533, 410 N 12th Street, Richmond, VA 23298, USA
Neurocrit Care 13:176-81. 2010..There is a paucity of studies comparing stress ulcer prophylaxis (SUP) agents in high-risk neurosurgical patients... - Amiloride for the prevention of amphotericin B-induced hypokalemia and hypomagnesemiaL D Wazny
Internal Medicine Nephrology, School of Pharmacy, Virginia Commonwealth University, Richmond 23298, USA
Ann Pharmacother 34:94-7. 2000..To review the published clinical data assessing the role of amiloride in the prevention of amphotericin B (AmB)induced electrolyte disorders... - Automated peritoneal dialysis: new implications for pharmacistsD F Brophy
Virginia Commonwealth University School of Pharmacy, Medical College of Virginia, Richmond 23298, USA
Ann Pharmacother 31:756-64. 1997..To review the new automated peritoneal dialysis (APD) modalities that are available to patients with end-stage renal disease (ESRD), and to examine their potential pharmacokinetic and drug dosing consequences... - Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunctionD F Brophy
Department of Pharmacy, Virginia Commonwealth University, Medical College of Virginia Campus, Richmond, Virginia, USA
J Thromb Haemost 2:1299-304. 2004..These results suggest that patients with renal dysfunction have a greater pharmacodynamic response to LMWH, independent of the pharmacokinetics of LMWH... - Development of an efficient sampling strategy to predict enoxaparin pharmacokinetics in stage 5 chronic kidney diseaseBrian R Overholser
Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Purdue University, Indianapolis and West Lafayette, Indiana 46202, USA
Ther Drug Monit 28:807-12. 2006..This sampling strategy may be used for therapeutic drug monitoring of enoxaparin and for future clinical trials in patients with chronic kidney disease... - Coagulopathy and traumatic shock: characterizing hemostatic function during the critical period prior to fluid resuscitationNathan J White
Department of Emergency Medicine, Virginia Commonwealth University, AD Williams Clinic 2nd Floor, Room 242, 1201 East Marshall Street, Richmond, VA 23298, USA
Resuscitation 81:111-6. 2010..A combat-relevant swine model was used to investigate the development of coagulopathy during trauma by monitoring hemostatic function during increasing severity of shock... - Venous thromboembolism prevention in acutely ill nonsurgical patientsDonald F Brophy
School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA
Ann Pharmacother 39:1318-24. 2005..CONCLUSIONS: Prophylaxis of VTE in acutely ill medical inpatients is underused. Data provide some guidance for increasing awareness and optimizing patient care... - The pharmacokinetics of subcutaneous enoxaparin in end-stage renal diseaseD F Brophy
Department of Primary Care, Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Virginia 23249, USA
Pharmacotherapy 21:169-74. 2001..CONCLUSIONS: Based on antifactor Xa activity, ESRD has little effect on the pharmacokinetics of enoxaparin, and dosing adjustments are unnecessary... - Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settingsJerry Siegel
College of Pharmacy, The Ohio State University Medical Center, Columbus 43210, USA
Am J Health Syst Pharm 65:1711-9. 2008..Erythropoiesis-stimulating agent (ESA) use in the outpatient and inpatient settings through pharmacist-conducted, hospital-based chart audits is examined and discussed...